2
|
Asif H, Ribeiro Neto M, Culver D. Pulmonary fibrosis in sarcoidosis. SARCOIDOSIS, VASCULITIS, AND DIFFUSE LUNG DISEASES : OFFICIAL JOURNAL OF WASOG 2023; 40:e2023027. [PMID: 37712364 PMCID: PMC10540713 DOI: 10.36141/svdld.v40i3.14830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 07/02/2023] [Accepted: 07/06/2023] [Indexed: 09/16/2023]
Abstract
Sarcoidosis may progress to pulmonary fibrosis in 5% of patients with significantly increased mortality. Histopathology shows fibrosis in a lymphangitic pattern surrounding the granulomas. Th1 to Th2 shift in environment along with angiogenesis is implicated in exuberant fibrosis. Clinical features include dyspnea, cough, and frequently with pulmonary function tests showing a mixed ventilatory defect with severely decreased diffusion capacity of carbon monoxide. Serologic markers including soluble interleukin 2 receptor, chitotriosidase and kern von den lunges 6, and chemokine ligand 18 are elevated and implicated in progression of disease. CT imaging shows fibrosis along bronchovascular bundles with reticulations, traction bronchiectasis and honeycombing predominantly in the upper and central distribution. Complications include sarcoidosis-associated pulmonary hypertension (SAPH) and chronic pulmonary aspergillosis. Treatment involves glucocorticoids and steroid-sparing agents in the presence of active granulomas. Anti-fibrotic agents such as pirfenidone and nintedanib have been shown to slow down pulmonary function decline in randomized clinical trials involving sarcoidosis-associated pulmonary fibrosis. Transplant workup is indicated in New York Heart Association class III or IV with similar success rates as in other lung transplant patients.
Collapse
Affiliation(s)
- Huda Asif
- University of South Florida, FL, USA .
| | | | | |
Collapse
|
3
|
Devcic J, Dussol M, Collin-Faure V, Pérard J, Fenel D, Schoehn G, Carrière M, Rabilloud T, Dalzon B. Immediate and Sustained Effects of Cobalt and Zinc-Containing Pigments on Macrophages. Front Immunol 2022; 13:865239. [PMID: 35928812 PMCID: PMC9343594 DOI: 10.3389/fimmu.2022.865239] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2022] [Accepted: 05/30/2022] [Indexed: 11/13/2022] Open
Abstract
Pigments are among the oldest nanoparticulate products known to mankind, and their use in tattoos is also very old. Nowadays, 25% of American people aged 18 to 50 are tattooed, which poses the question of the delayed effects of tattoos. In this article, we investigated three cobalt [Pigment Violet 14 (purple color)] or cobalt alloy pigments [Pigment Blue 28 (blue color), Pigment Green 14 (green color)], and one zinc pigment [Pigment White 4 (white color)] which constitute a wide range of colors found in tattoos. These pigments contain microparticles and a significant proportion of submicroparticles or nanoparticles (in either aggregate or free form). Because of the key role of macrophages in the scavenging of particulate materials, we tested the effects of cobalt- and zinc-based pigments on the J774A.1 macrophage cell line. In order to detect delayed effects, we compared two exposure schemes: acute exposure for 24 hours and an exposure for 24 hours followed by a 3-day post-exposure recovery period. The conjunction of these two schemes allowed for the investigation of the delayed or sustained effects of pigments. All pigments induced functional effects on macrophages, most of which were pigment-dependent. For example, Pigment Green 19, Pigment Blue 28, and Pigment White 4 showed a delayed alteration of the phagocytic capacity of cells. Moreover, all the pigments tested induced a slight but significant increase in tumor necrosis factor secretion. This effect, however, was transitory. Conversely, only Pigment Blue 28 induced both a short and sustained increase in interleukin 6 secretion. Results showed that in response to bacterial stimuli (LPS), the secretion of tumor necrosis factor and interleukin 6 declined after exposure to pigments followed by a recovery period. For chemoattractant cytokines (MCP-1 or MIP-1α), delayed effects were observed with a secretion decreased in presence of Pigment Blue 28 and Pigment violet 14, both with or without LPS stimuli. The pigments also induced persisting changes in some important macrophage membrane markers such as CD11b, an integrin contributing to cell adhesion and immunological tolerance. In conclusion, the pigments induced functional disorders in macrophages, which, in some cases, persist long after exposure, even at non-toxic doses.
Collapse
Affiliation(s)
- Julie Devcic
- Chemistry and Biology of Metals, Université Grenoble Alpes, Centre National de la recherche Scientifique (CNRS) UMR5249, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Institut de Recherche Interdisciplinaire de Grenoble, (IRIG)-Département des Interfaces pour l’Energie, la Santé et l’Environnement (DIESE)-Laboratoire de Chimie et Biologie des Métaux (LCBM)- Équipe Protéomique pour la Microbiologie, l'Immunologie et la Toxicologie (ProMIT), Grenoble, France
| | - Manon Dussol
- Université Grenoble-Alpes, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Centre National de la recherche Scientifique (CNRS), Institut de Recherche Interdisciplinaire de Grenoble (IRIG)-Département des Interfaces pour l’Energie, la Santé et l’Environnement (DIESE), Systèmes Moléculaires et nanoMatériaux pour l’Energie et la Santé (SyMMES), Chemistry Interface Biology for the Environment, Health and Toxicology (CIBEST), Grenoble, France
| | - Véronique Collin-Faure
- Chemistry and Biology of Metals, Université Grenoble Alpes, Centre National de la recherche Scientifique (CNRS) UMR5249, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Institut de Recherche Interdisciplinaire de Grenoble, (IRIG)-Département des Interfaces pour l’Energie, la Santé et l’Environnement (DIESE)-Laboratoire de Chimie et Biologie des Métaux (LCBM)- Équipe Protéomique pour la Microbiologie, l'Immunologie et la Toxicologie (ProMIT), Grenoble, France
| | - Julien Pérard
- Chemistry and Biology of Metals, Université Grenoble Alpes, Centre National de la recherche Scientifique (CNRS) UMR5249, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Institut de Recherche Interdisciplinaire de Grenoble, (IRIG)-Département des Interfaces pour l’Energie, la Santé et l’Environnement (DIESE)-Laboratoire de Chimie et Biologie des Métaux (LCBM)- Équipe Protéomique pour la Microbiologie, l'Immunologie et la Toxicologie (ProMIT), Grenoble, France
| | - Daphna Fenel
- Univ. Grenoble Alpes, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Centre National de la recherche Scientifique (CNRS), Institut de Biologie Structurale (IBS), Grenoble, France
| | - Guy Schoehn
- Univ. Grenoble Alpes, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Centre National de la recherche Scientifique (CNRS), Institut de Biologie Structurale (IBS), Grenoble, France
| | - Marie Carrière
- Université Grenoble-Alpes, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Centre National de la recherche Scientifique (CNRS), Institut de Recherche Interdisciplinaire de Grenoble (IRIG)-Département des Interfaces pour l’Energie, la Santé et l’Environnement (DIESE), Systèmes Moléculaires et nanoMatériaux pour l’Energie et la Santé (SyMMES), Chemistry Interface Biology for the Environment, Health and Toxicology (CIBEST), Grenoble, France
| | - Thierry Rabilloud
- Chemistry and Biology of Metals, Université Grenoble Alpes, Centre National de la recherche Scientifique (CNRS) UMR5249, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Institut de Recherche Interdisciplinaire de Grenoble, (IRIG)-Département des Interfaces pour l’Energie, la Santé et l’Environnement (DIESE)-Laboratoire de Chimie et Biologie des Métaux (LCBM)- Équipe Protéomique pour la Microbiologie, l'Immunologie et la Toxicologie (ProMIT), Grenoble, France
- *Correspondence: Thierry Rabilloud, ; Bastien Dalzon,
| | - Bastien Dalzon
- Chemistry and Biology of Metals, Université Grenoble Alpes, Centre National de la recherche Scientifique (CNRS) UMR5249, Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Institut de Recherche Interdisciplinaire de Grenoble, (IRIG)-Département des Interfaces pour l’Energie, la Santé et l’Environnement (DIESE)-Laboratoire de Chimie et Biologie des Métaux (LCBM)- Équipe Protéomique pour la Microbiologie, l'Immunologie et la Toxicologie (ProMIT), Grenoble, France
- *Correspondence: Thierry Rabilloud, ; Bastien Dalzon,
| |
Collapse
|
4
|
Venditto VJ, Feola DJ. Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions. Adv Drug Deliv Rev 2022; 184:114252. [PMID: 35367307 PMCID: PMC9063468 DOI: 10.1016/j.addr.2022.114252] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 03/07/2022] [Accepted: 03/28/2022] [Indexed: 12/17/2022]
Abstract
Drug carriers to deliver macrolide antibiotics, such as azithromycin, show promise as antibacterial agents. Macrolide drug carriers have largely focused on improving the drug stability and pharmacokinetics, while reducing adverse reactions and improving antibacterial activity. Recently, macrolides have shown promise in treating inflammatory conditions by promoting a reparative effect and limiting detrimental pro-inflammatory responses, which shifts the immunologic setpoint from suppression to balance. While macrolide drug carriers have only recently been investigated for their ability to modulate immune responses, the previous strategies that deliver macrolides for antibacterial therapy provide a roadmap for repurposing the macrolide drug carriers for therapeutic interventions targeting inflammatory conditions. This review describes the antibacterial and immunomodulatory activity of macrolides, while assessing the past in vivo evaluation of drug carriers used to deliver macrolides with the intention of presenting a case for increased effort to translate macrolide drug carriers into the clinic.
Collapse
|
5
|
Autophagy and Mitophagy-Related Pathways at the Crossroads of Genetic Pathways Involved in Familial Sarcoidosis and Host-Pathogen Interactions Induced by Coronaviruses. Cells 2021; 10:cells10081995. [PMID: 34440765 PMCID: PMC8393644 DOI: 10.3390/cells10081995] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Revised: 07/16/2021] [Accepted: 07/29/2021] [Indexed: 12/12/2022] Open
Abstract
Sarcoidosis is a multisystem disease characterized by the development and accumulation of granulomas, the hallmark of an inflammatory process induced by environmental and/or infectious and or genetic factors. This auto-inflammatory disease mainly affects the lungs, the gateway to environmental aggressions and viral infections. We have shown previously that genetic predisposition to sarcoidosis occurring in familial cases is related to a large spectrum of pathogenic variants with, however, a clustering around mTOR (mammalian Target Of Rapamycin)-related pathways and autophagy regulation. The context of the COVID-19 pandemic led us to evaluate whether such genetic defects may increase the risk of a severe course of SARS-CoV2 infection in patients with sarcoidosis. We extended a whole exome screening to 13 families predisposed to sarcoidosis and crossed the genes sharing mutations with the list of genes involved in the SARS-CoV2 host-pathogen protein-protein interactome. A similar analysis protocol was applied to a series of 100 healthy individuals. Using ENRICH.R, a comprehensive gene set enrichment web server, we identified the functional pathways represented in the set of genes carrying deleterious mutations and confirmed the overrepresentation of autophagy- and mitophagy-related functions in familial cases of sarcoidosis. The same protocol was applied to the set of genes common to sarcoidosis and the SARS-CoV2-host interactome and found a significant enrichment of genes related to mitochondrial factors involved in autophagy, mitophagy, and RIG-I-like (Retinoic Acid Inducible Gene 1) Receptor antiviral response signaling. From these results, we discuss the hypothesis according to which sarcoidosis is a model for studying genetic abnormalities associated with host response to viral infections as a consequence of defects in autophagy and mitophagy processes.
Collapse
|
6
|
Jabbari P, Sadeghalvad M, Rezaei N. An inflammatory triangle in Sarcoidosis: PPAR-γ, immune microenvironment, and inflammation. Expert Opin Biol Ther 2021; 21:1451-1459. [PMID: 33798017 DOI: 10.1080/14712598.2021.1913118] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
INTRODUCTION Sarcoidosis is an inflammatory disorder characterized by granuloma formation in several organs. Sarcoidosis patients experience higher inflammatory responses resulting in pulmonary fibrosis. Although the precise mechanisms have not been well elucidated, the relationship between the immune system activation and inflammatory status is pivotal in the pathogenesis of sarcoidosis. AREAS COVERED Peroxisome proliferator-activated receptor (PPAR) includes the transcription factors involved in cell metabolism, proliferation, and immune response. In the alveolar macrophages of patients with sarcoidosis, the reduced activity and a decreased level of PPAR-γ have been shown. In this study, we discuss how reducing the level of PPAR-γ could lead to increased inflammation and immune responses in patients with sarcoidosis. EXPERT OPINION Lack of PPAR-γ may contribute to the development of a suitable milieu for the formation of immune-associated pulmonary granuloma. Reduced levels of PPAR-γ in sarcoidosis could result from over-activation of the immune system and elevated inflammatory responses, as well. Due to the anti-inflammatory function of PPAR-γ, identifying the relation between PPAR-γ, sarcoidosis development, and inflammatory state could be essential to identify the appropriate therapeutic targets. The synthesis of PPAR-γ agonists or PPAR-γ ligands may be an effective step toward the treatment of sarcoidosis patients in the future.
Collapse
Affiliation(s)
- Parnia Jabbari
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.,Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Mona Sadeghalvad
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.,Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Nima Rezaei
- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.,Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.,Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
7
|
Calcagno TM, Zhang C, Tian R, Ebrahimi B, Mirsaeidi M. Novel three-dimensional biochip pulmonary sarcoidosis model. PLoS One 2021; 16:e0245805. [PMID: 33539409 PMCID: PMC7861546 DOI: 10.1371/journal.pone.0245805] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Accepted: 01/07/2021] [Indexed: 02/07/2023] Open
Abstract
Sarcoidosis is a multi-system disorder of granulomatous inflammation which most commonly affects the lungs. Its etiology and pathogenesis are not well defined in part due to the lack of reliable modeling. Here, we present the development of an in vitro three-dimensional lung-on-chip biochip designed to mimic granuloma formation. A lung on chip fluidic macrodevice was developed and added to our previously developed a lung-on-membrane model (LOMM). Granulomas were cultured from blood samples of patients with sarcoidosis and then inserted in the air-lung-interface of the microchip to create a three-dimensional biochip pulmonary sarcoidosis model (3D BSGM). Cytokines were measured after 48 hours. ELISA testing was performed to measure cytokine response difference between LOMM with 3D BSGM. There were statistically significant differences in IL-1ß (P = 0.001953), IL-6 (P = 0.001953), GM-CSF (P = 0.001953), and INF-γ expressions (P = 0.09375) between two groups. The current model represents the first 3D biochip sarcoidosis model created by adding a microfluidics system to a dual-chambered lung on membrane model and introducing developed sarcoid-granuloma to its air-lung-interface.
Collapse
Affiliation(s)
- Tess M. Calcagno
- Department of Medicine, University of Miami, Miami, FL, United States of America
| | - Chongxu Zhang
- Division of Pulmonary and Critical Care, University of Miami, Miami, FL, United States of America
| | - Runxia Tian
- Division of Pulmonary and Critical Care, University of Miami, Miami, FL, United States of America
| | - Babak Ebrahimi
- Research and Development, Genix-Engineering, Irvin, California, United States of America
| | - Mehdi Mirsaeidi
- Division of Pulmonary and Critical Care, University of Miami, Miami, FL, United States of America
- * E-mail:
| |
Collapse
|
8
|
Locke LW, Schlesinger LS, Crouser ED. Current Sarcoidosis Models and the Importance of Focusing on the Granuloma. Front Immunol 2020; 11:1719. [PMID: 32849608 PMCID: PMC7417311 DOI: 10.3389/fimmu.2020.01719] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Accepted: 06/29/2020] [Indexed: 12/24/2022] Open
Abstract
The inability to effectively model sarcoidosis in the laboratory or in animals continues to hinder the discovery and translation of new, targeted treatments. The granuloma is the signature pathological hallmark of sarcoidosis, yet there are significant knowledge gaps that exist with regard to how granulomas form. Significant progress toward improved therapeutic and prognostic strategies in sarcoidosis hinges on tractable experimental models that recapitulate the process of granuloma formation in sarcoidosis and allow for mechanistic insights into the molecular events involved. Through its inherent representation of the complex genetics underpinning immune cell dysregulation in sarcoidosis, a recently developed in vitro human granuloma model holds promise in providing detailed mechanistic insight into sarcoidosis–specific disease regulating pathways at play during early stages of granuloma formation. The purpose of this review is to critically evaluate current sarcoidosis models and assess their potential to progress the field toward the goal of improved therapies in this disease. We conclude with the potential integrated use of preclinical models to accelerate progress toward identifying and testing new drugs and drug combinations that can be rapidly brought to clinical trials.
Collapse
Affiliation(s)
- Landon W Locke
- Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, United States
| | - Larry S Schlesinger
- Host-Pathogens Interactions Program, Texas Biomedical Research Institute, San Antonio, TX, United States
| | - Elliott D Crouser
- Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, The Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, United States
| |
Collapse
|